JJ
John E. (Jack) Bailey Jr.
President and CEO

John E. (Jack) Bailey Jr. insider trades: G1 Therapeutics (GTHX) stock buys and sales

President and CEO, G1 Therapeutics Last trade Jul 5, 2024 14 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
8
Open-market trades
since 2020
1
Company
last trade 2024

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where John reports to the SEC

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jul 5, 2024GTHX↓ Sell$19K
May 13, 2024GTHX↓ Sell$178K
Jan 3, 2024GTHX↓ Sell$36K
Jan 2, 2024GTHX↓ Sell$108K
Jul 5, 2023GTHX↓ Sell10b5-1$7K
Jan 4, 2023GTHX↓ Sell$219K
Jan 3, 2022GTHX↓ Sell$355K
Nov 11, 2020GTHX↑ Buy$102K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About John E. (Jack) Bailey Jr.'s insider trades

John E. (Jack) Bailey Jr. is President and CEO at G1 Therapeutics (GTHX). Since Nov 11, 2020, John has reported 1 open-market purchase worth $102K and 7 sales worth $923K on SEC Form 4. There have been no open-market trades in the last 12 months.

1 sale (1% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.

Their filings also include grants and awards (9 filings), shares returned to the company (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every GTHX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.